P3, N=264, Active, not recruiting, University Hospital, Rouen | Recruiting --> Active, not recruiting

P1, N=112, Recruiting, Sun Pharmaceutical Industries Limited | Not yet recruiting --> Recruiting

P3, N=500, Recruiting, Centre Hospitalier Intercommunal Creteil | Trial primary completion date: Feb 2026 --> Feb 2029

P1, N=42, Completed, University of Wisconsin, Madison | N=110 --> 42

This study provides one of the first extensive characterizations of PV in southern Colombia, confirming internationally recognized clinical features, including advanced age at diagnosis, increased prevalence of cardiovascular comorbidities, and a predominance of high-risk classification. The low rate of finding JAK2 mutations suggests that molecular testing may not be as easy to get as it could be. Even if the treatment followed the guidelines, the risk of recurrence and thrombosis remained, showing that PV is a long-term and worsening condition. These findings highlight the urgent need to expand access to molecular diagnostics, develop tailored risk-adapted medicines, and initiate prospective multicenter studies in Latin America to optimize outcomes and quality of life in PV.

P4, N=60, Recruiting, University Hospital, Bordeaux | Trial completion date: May 2024 --> May 2027 | Trial primary completion date: May 2024 --> May 2027

Interestingly, PTS did not interfere with COX-2 inhibition when cells were treated with the non-selective inhibitor Indomethacin. These findings suggest that PTS influences stress response and survival pathways in a context-dependent manner. However, mechanistic crosstalk between NrfF2, NF-κB, COX-2, and GSK-3β remains to be established.

P3, N=360, Completed, Oslo University Hospital | Recruiting --> Completed | Trial completion date: Nov 2026 --> Jun 2026 | Trial primary completion date: Nov 2026 --> Jun 2026

Colorectal cancer treatment is increasingly evolving into a precision oncology approach. Integration of molecular biomarkers enables tailored therapy decisions and opens new options, particularly in adjuvant and metastatic settings.

The prodrug of CPX, fosciclopirox, was evaluated for safety and preliminary efficacy in patients with advanced solid tumors, including bladder cancer, and was found to inhibit cell proliferation, the γ-secretase complex, and Notch signaling. Mechanistically, CPX modulates Notch1 activation temporally and reprograms T cell metabolism by limiting glycolysis, both of which impact proliferative and effector responses in activated T cells. Together, these findings identify CPX as a modulator of T cell immunity, highlighting the broader immunologic implications for its therapeutic application.

P=N/A, N=2641, Recruiting, IRCCS San Raffaele Roma | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

Sixty rats were separated into 4 groups structured as: control group; ulcerated group; Cana group; Omeprazole group. Additionally, it restored intestinal permeability, which, in turn, aggravated peptic ulcer via endotoxemia. Hence, Cana is a promising gastroprotective agent against peptic ulcers through multiple cascades, evidenced by network pharmacology and experimental validation.